Egetis Therapeutics is focused on developing innovative therapies for serious diseases, particularly within the orphan drug segment, which addresses significant unmet medical needs. Their lead product candidate, Emcitate® (tiratricol), is aimed at treating MCT8 deficiency, a rare genetic disorder that affects the transport of thyroid hormones into the central nervous system. This condition, primarily impacting males due to its X-linked inheritance pattern, leads to severe neurodevelopmental issues, including intellectual disability and psychomotor delays. Egetis is committed to advancing this therapy through clinical trials to provide a much-needed treatment option for affected patients.

In addition to Emcitate®, Egetis is also developing Aladote®, a treatment for paracetamol (acetaminophen) overdose, which is a common and serious medical issue worldwide. Paracetamol poisoning can lead to acute liver failure, necessitating urgent medical intervention. Egetis recognizes the critical need for effective therapies in this area, as paracetamol overdoses result in significant healthcare burdens, including emergency department visits and hospital admissions. By focusing on these two key therapeutic areas, Egetis aims to make a meaningful impact on the lives of patients suffering from rare and life-threatening conditions.

Sweden

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics

Company Details